MedTrace Logo

Ultra-low-dose Chest CT for HHT

NCT04874558 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3

Last updated 2026-04-24

No results posted yet for this study

Summary

This study aims to develop a novel ultra-low dose chest CT technology for use in Hereditary Hemorrhagic Teleangiectasia (HHT) patients and to determine the lowest possible radiation dose that is achievable without sacrificing the diagnostic quality.

Conditions

  • Hereditary Hemorrhagic Telangiectasia

Interventions

DIAGNOSTIC_TEST

Ultra-low dose chest CT

A novel CT technique with a new dose optimization and efficiency technology and automatic kV selection, which greatly reduces the dose of radiation exposure compared to a standard chest CT.

Sponsors & Collaborators

Principal Investigators

  • Nadir Demirel, MD · Mayo Clinic

Eligibility

Min Age
1 Year
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-21
Primary Completion
2025-12-31
Completion
2026-03-07

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04874558 on ClinicalTrials.gov